Treat type 2 diabetes 'like cancer': How THIS major complication can lead to early death
TYPE 2 diabetes should be treated like cancer - and more focus should be placed on foot ulcers which can be fatal, an expert has claimed. (Source: Daily Express - Health)
Source: Daily Express - Health - June 16, 2017 Category: Consumer Health News Source Type: news
UA surgeon: Physicians, patients must focus on remission of diabetic ulcers
(University of Arizona) Physicians and patients need to focus on remission of diabetic ulcers -- that is, extending the time between their formation, says Dr. David G. Armstrong, professor of surgery and director of the Southern Arizona Limb Salvage Alliance at the University of Arizona College of Medicine - Tucson. Armstrong says extending patients' ulcer-free days using treatment and prevention is essential, according to a report from Armstrong and his co-authors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 14, 2017 Category: International Medicine & Public Health Source Type: news
Sanuwave Health inks dev deal with eKare for wound care integration
Sanuwave Health (OTC:SNWV) said today it entered a memorandum of understanding with eKare to develop novel wound care analysis and management solutions which integrates technology from both companies.
Through the deal, Sanuwave’s dermaPace wound treatment device will be linked with eKare’s inSight 3D wound imaging and analytics system to produce a comprehensive wound management solution, Suwanee, Ga.-based Sanuwave said.
“We are excited to be teaming with Sanuwave to elevate inSight’s strength in imaging and analytics to develop better treatment algorithms for the dermaPace solution. This potent co...
Source: Mass Device - June 8, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Research & Development Wound Care ekare SANUWAVE Health Inc. Source Type: news
Type 2 diabetes symptoms - THIS item of clothing could be making condition worse
TYPE 2 DIABETES is a serious health condition, and if symptoms aren't properly treated it can cause complications such as foot ulcers and even amputation. (Source: Daily Express - Health)
Source: Daily Express - Health - June 1, 2017 Category: Consumer Health News Source Type: news
Pretibial Myxedema Masquerading as a Venous Leg Ulcer Pretibial Myxedema Masquerading as a Venous Leg Ulcer
A case of non-healing leg ulcers ultimately reveals a diagnosis of pretibial myxedema. How was this difficult case diagnosed?Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 29, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Sanuwave Health taps Lithomed as Taiwanese ortho distributor
Sanuwave Health (OTC:SNWV) said today it tapped Lithomed as its orthopedic product distributor in Taiwan.
Suwanee, Ga.-based Sanuwave said the selection of Lithomed was the result of an extensive search in the region, and that the contract comes with a minimum order value of $500,000.
“Sanuwave has committed to deliver 3-5 new distribution partners in the second quarter and 7-10 by the end of the year. This is the first step in achieving or beating our target. We are also excited to be able to support our science advisor Dr. Chin-Jen Wang, Professor of Orthopedic Surgery at Chang Gung Memorial Hospital, and his n...
Source: Mass Device - May 25, 2017 Category: Medical Devices Authors: Fink Densford Tags: Distribution Orthopedics SANUWAVE Health Inc. Source Type: news
Foot mat may help predict who will get a common diabetes complication
An experimental foot-temperature monitoring system might one day be able to detect when diabetic patients are developing foot ulcers, a common complication that can lead to infections and amputations, a small study suggests. (Source: Reuters: Health)
Source: Reuters: Health - May 24, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)
Based on new data from two large clinical trials, FDA has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. We are requiring new warnings, including our most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk. Patients taking canagliflozin should notify your health care professionals right away if you develop new pain or tenderness, sores or ulcers, or infections in your legs or feet. Talk to your healthcare professional if you have questions or concerns. Do not stop taking your diabete...
Source: FDA Center for Drug Evaluation and Research - What's New - May 16, 2017 Category: Drugs & Pharmacology Source Type: news
' Smart Mat' Predicts 97% of Recurrent Diabetic Foot Ulcers'Smart Mat' Predicts 97% of Recurrent Diabetic Foot Ulcers
A wireless foot-temperature-monitoring mat predicts diabetic foot ulcers with 97% accuracy in high-risk patients -- those with previously healed ulcers. False positives were an issue in the study, however.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 10, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
An External Fixator When Offloading Is Not an Option An External Fixator When Offloading Is Not an Option
This case report discusses the use of an external fixator for a diabetic plantar foot ulcer when traditional offloading techniques were not viable options.Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 1, 2017 Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news
Human Reticular Acellular Dermal for Diabetic Foot Ulcers Human Reticular Acellular Dermal for Diabetic Foot Ulcers
A human reticular acellular dermal matrix may offer an effective alternative for diabetic foot ulcers that did not heal with the standard of care treatment.Wounds (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 24, 2017 Category: Surgery Tags: Diabetes & Endocrinology Journal Article Source Type: news
The Use of a Sea Salt-Based Spray for Diabetic Foot Ulcers The Use of a Sea Salt-Based Spray for Diabetic Foot Ulcers
A novel sea salt-based wound care spray may be a viable option in the treatment of diabetic foot ulcers.Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 17, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
7 medtech stories we missed this week: April 7, 2017
[Image from unsplash.com]New studies for umbilical cord allografts and tumor targeting were published this week while another company received European CE Marking.
Here are some medtech stories we missed this week but thought were still worth mentioning.
1. AMNIOX touts new umbilical cord study
AMNIOX Medical announced that it has published the results of 3 studies that demonstrate the effectiveness of umbilical cord tissue for treating chronic wounds, according to an April 7 press release. The company’s cryopreserved human umbilical cord tissue, NEOX Cord 1K was tested on 29 patients who needed a wound allograft to tr...
Source: Mass Device - April 7, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Clinical Trials Radiosurgery Regulatory/Compliance Research & Development Spinal Wound Care Aesculap Implant Systems Amniox AngioDynamics Cianna Medical InVivo Therapeutics MedTech Nu-Med Occlutech Source Type: news
Mayo Clinic Minute: Steps to diabetic foot care
People with diabetes face many health problems, including nerve damage and poor blood circulation. These problems make their feet vulnerable to skin sores (ulcers) that can worsen quickly and are difficult to treat.?The good news is that proper diabetes management and careful foot care can help prevent foot ulcers. The American Diabetes Association has named [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 28, 2017 Category: Databases & Libraries Source Type: news
Origin treats first patients in study of nitric oxide for diabetic foot ulcers
Origin said today that it treated the 1st patients in its dose-ranging Genesis Phase IIb-equivalent trial. The study is evaluating therapeutic quantities of plasma-generated nitric oxide as a treatment for chronic diabetic foot ulcers.
The 27-week trial is slated to enroll up to 100 patients. Patients will be randomized into 1 of 4 dosing regimens, or receive standard of care as a control, to assess the safety and efficacy of plasma-generated nitric oxide, according to Origin. The company plans to treat the participants for 12 weeks and monitor them for 12 weeks following treatment.
Get the full story at our sister site, ...
Source: Mass Device - March 22, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Drug-Device Combinations Wall Street Beat Wound Care Origin Source Type: news
